Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis

Current Opinion in Infectious Diseases

Volumn 25, Issue 4, 2012, Pages 458-463

  Mejia, Rojelio ^a   Nutman, Thomas B ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

anthelmintic therapy; immunocompromised; infection; screening; Strongyloides

Indexed keywords

ALBENDAZOLE; AZATHIOPRINE; BLEOMYCIN; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; ETANERCEPT; IFOSFAMIDE; IMMUNOGLOBULIN E; INFLIXIMAB; IVERMECTIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; THYMOCYTE ANTIBODY; TIABENDAZOLE; VINCA ALKALOID;

BODY FLUID; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISSEMINATED INFECTION; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHILIA; FECES ANALYSIS; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERINFECTION SYNDROME; IMMUNOCOMPROMISED PATIENT; IMMUNOGLOBULIN DEFICIENCY; IMMUNOPRECIPITATION; INFECTION; LUNG LAVAGE; MORTALITY; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; PLEURA FLUID; PURPURA; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; WHOLE BODY RADIATION;

ACUTE DISEASE; ANIMALS; ANTINEMATODAL AGENTS; CHRONIC DISEASE; EARLY DIAGNOSIS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; RISK FACTORS; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS;

EID: 84863727271     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283551dbd     Document Type: Review

References (52)

1. Olsen A, van Lieshout L, Marti H, et al. Strongyloidiasis-the most neglected of the neglected tropical diseases? Trans R Soc Trop Med Hyg 2009; 103:967-972.
2. Dada-Adegbola HO, Oluwatoba OA, Bakare RA. Strongyloidiasis: prevalence, risk factors, clinical and laboratory features among diarrhea patients in Ibadan Nigeria. Afr J Med Med Sci 2010; 39:285-292.
3. Knopp S, Mohammed KA, Simba Khamis I, et al. Spatial distribution of soiltransmitted helminths, including Strongyloides stercoralis, among children in Zanzibar. Geospat Health 2008; 3:47-56.
4. Zeehaida M, Zairi NZ, Rahmah N, et al. Strongyloides stercoralis in common vegetables and herbs in Kota Bharu, Kelantan, Malaysia. Trop Biomed 2011; 28:188-193.
5. Rivera E, Maldonado N, Velez-Garcia E, et al. Hyperinfection syndrome with Strongyloides stercoralis. Ann Intern Med 1970; 72:199-204.
6. Prendki V, Fenaux P, Durand R, et al. Strongyloidiasis in man 75 years after initial exposure. Emerg Infect Dis 2011; 17:931-932.
7. Rossi CL, Takahashi EE, Partel CD, et al. Total serum IgE and parasitespecific IgG and IgA antibodies in human strongyloidiasis. Rev Inst Med Trop Sao Paulo 1993; 35:361-365.
8. Baaten GG, Sonder GJ, van Gool T, et al. Travel-related schistosomiasis, strongyloidiasis, filariasis, and toxocariasis: the risk of infection and the diagnostic relevance of blood eosinophilia. BMC Infect Dis 2011; 11:84.
9. Richter J, Muller-Stover I, Strothmeyer H, et al. Arthritis associated with Strongyloides stercoralis infection in HLA B-27-positive African. Parasitol Res 2006; 99:706-707. (Pubitemid 44510622)
10. Copelovitch L, Sam Ol O, Taraquinio S, Chanpheaktra N. Childhood nephrotic syndrome in Cambodia: an association with gastrointestinal parasites. J Pediatr 2010; 156:76-81.
11. Atul S, Ajay D, Ritambhara N, et al. An unusual cause of malabsorption in an immunocompetent host. J Ayub Med Coll Abbottabad 2005; 17:85-86.
12. Hindy P, Parvin R, Hanna K, Gress F. Strongyloidiasis presenting as duodenal obstruction in a patient infected with human T-cell lymphotropic virus type 1. Gastrointest Endosc 2011; 74:439-441.
13. Gulbas Z, Kebapci M, Pasaoglu O, Vardareli E. Successful ivermectin treatment of hepatic strongyloidiasis presenting with severe eosinophilia. South Med J 2004; 97:907-910. (Pubitemid 39249679)
14. Kuzucu A. Parasitic diseases of the respiratory tract. Curr Opin Pulm Med 2006; 12:212-221. (Pubitemid 44350477)
15. Hauber HP, Galle J, Chiodini PL, et al. Fatal outcome of a hyperinfection syndrome despite successful eradication of Strongyloides with subcutaneous ivermectin. Infection 2005; 33:383-386. (Pubitemid 41552019)
16. Yoshida H, Endo H, Tanaka S, et al. Recurrent paralytic ileus associated with strongyloidiasis in a patient with systemic lupus erythematosus. Mod Rheumatol 2006; 16:44-47.
17. Basile A, Simzar S, Bentow J, et al. Disseminated Strongyloides stercoralis: hyperinfection during medical immunosuppression. J Am Acad Dermatol 2010; 63:896-902.
18. Shorman M, Al-Tawfiq JA. Strongyloides stercoralis hyperinfection presenting as acute respiratory failure and Gram-negative sepsis in a patient with astrocytoma. Int J Infect Dis 2009; 13:e288-e291.
19. Satyanarayana S, Nema S, Kalghatgi AT, et al. Disseminated Strongyloides stercoralis in AIDS: a report from India. Ind J Pathol Microbiol 2005; 48:472-474. (Pubitemid 41769524)
20. De Silva T, Raychaudhuri M, Poulton M. HIV infection associated with Strongyloides stercoralis colitis resulting in Streptococcus bovis bacteraemia and meningitis. Sex Transm Infect 2005; 81:276-277. (Pubitemid 40835060)
21. Lam CS, Tong MK, Chan KM, Siu YP. Disseminated strongyloidiasis: a retrospective study of clinical course and outcome. Eur J Clin Microbiol Infect Dis 2006; 25:14-18. (Pubitemid 43207323)
22. Stewart DM, Ramanathan R, Mahanty S, et al. Disseminated Strongyloides stercoralis infection in HTLV-1-associated adult T-cell leukemia/lymphoma. Acta Haematol 2011; 126:63-67.
23. Ghosh K. Strongyloides stercoralis septicaemia following steroid therapy for eosinophilia: report of three cases. Trans R Soc Trop Med Hyg 2007; 101:1163-1165. (Pubitemid 47440536)
24. Carvalho EM, Da Fonseca Porto A. Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis. Parasite Immunol 2004; 26:487-497. (Pubitemid 40461165)
25. Marcos LA, Terashima A, Canales M, Gotuzzo E. Update on strongyloidiasis in the immunocompromised host. Curr Infect Dis Rep 2011; 13:35-46.
26. Gotuzzo E, Arango C, de Queiroz-Campos A, Isturiz RE. Human T-cell lymphotropic virus-I in Latin America. Infect Dis Clin North Am 2000; 14:211-239. (Pubitemid 30158548)
27. Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev 2004; 17:208-217. (Pubitemid 38120934)
28. Walson JL, Stewart BT, Sangare L, et al. Prevalence and correlates of helminth co-infection in Kenyan HIV-1 infected adults. PLoS Negl Trop Dis 2010; 4:e644.
29. Celedon JC, Mathur-Wagh U, Fox J, et al. Systemic strongyloidiasis in patients infected with the human immunodeficiency virus. A report of 3 cases and review of the literature. Medicine (Baltimore) 1994; 73:256-263.
30. Mascarello M, Gobbi F, Angheben A, et al. Prevalence of Strongyloides stercoralis infection among HIV-positive immigrants attending two Italian hospitals, from 2000 to 2009. Ann Trop Med Parasitol 2011; 105:617-623.
31. Brown M, Cartledge JD, Miller RF. Dissemination of Strongyloides stercoralis as an immune restoration phenomenon in an HIV-1-infected man on antiretroviral therapy. Int J STD AIDS 2006; 17:560-561. (Pubitemid 44285733)
32. Wirk B, Wingard JR. Strongyloides stercoralis hyperinfection in hematopoietic stem cell transplantation. Transplant Infect Dis 2009; 11:143-148.
33. Corradini P, Farina L. Allogeneic transplantation for lymphoma: long-term outcome. Curr Opin Hematol 2010; 17:522-530.
34. Choi S, Reddy P. Graft-versus-host disease. Panminerva Med 2010; 52: 111-124.
35. Rotterdam H, Tsang P. Gastrointestinal disease in the immunocompromised patient. Hum Pathol 1994; 25:1123-1140. (Pubitemid 24351496)
36. Wolfe RA, Roys EC, Merion RM. Trends in organ donation and transplantation in the United States, 1999-2008. Am J Transplant 2010; 10:961-972.
37. Weiser JA, Scully BE, Bulman WA, et al. Periumbilical parasitic thumbprint purpura: strongyloides hyperinfection syndrome acquired from a cadaveric renal transplant. Transplant Infect Dis 2011; 13:58-62.
38. Seet RC, Lau LG, Tambyah PA. Strongyloides hyperinfection and hypogammaglobulinemia. Clin Diagn Lab Immunol 2005; 12:680-682. (Pubitemid 41184733)
39. Yassin MA, El Omri H, Al-Hijji I, et al. Fatal Strongyloides stercoralis hyperinfection in a patient with multiple myeloma. Braz J Infect Dis 2010; 14:536-539.
40. Hsieh YP, Wen YK, Chen ML. Minimal change nephrotic syndrome in association with strongyloidiasis. Clin Nephrol 2006; 66:459-463. (Pubitemid 44896156)
41. Cartwright CP. Utility of multiple-stool-specimen ova and parasite examinations in a high-prevalence setting. J Clin Microbiol 1999; 37:2408-2411. (Pubitemid 29337253)
42. Krolewiecki AJ, Ramanathan R, Fink V, et al. Improved diagnosis of Strongyloides stercoralis using recombinant antigen-based serologies in a community-wide study in northern Argentina. Clin Vaccine Immunol 2010; 17:1624-1630.
43. Ramanathan R, Nutman TB. Strongyloides stercoralis infection in the immunocompromised host. Curr Infect Dis Rep 2008; 10:105-110.
44. Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis 2001; 33:1040-1047. (Pubitemid 32907108)
45. Taniuchi M, Verweij JJ, Noor Z, et al. High throughput multiplex PCR and probe-based detection with Luminex beads for seven intestinal parasites. Am J Trop Med Hyg 2011; 84:332-337.
46. Ten Hove RJ, van Esbroeck M, Vervoort T, et al. Molecular diagnostics of intestinal parasites in returning travellers. Eur J Clin Microbiol Infect Dis 2009; 28:1045-1053.
47. Ramanathan R, Burbelo PD, Groot S, et al. A luciferase immunoprecipitation systems assay enhances the sensitivity and specificity of diagnosis of Strongyloides stercoralis infection. J Infect Dis 2008; 198:444-451.
48. Suputtamongkol Y, Premasathian N, Bhumimuang K, et al. Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis. PLoS Negl Trop Dis 2011; 5:e1044.
49. Pornsuriyasak P, Niticharoenpong K, Sakapibunnan A. Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: a case report of intractable strongyloidiasis. Southeast Asian J Trop Health Hyg 2004; 35:531-534. (Pubitemid 39486416)
50. Grein JD, Mathisen GE, Donovan S, Fleckenstein L. Serum ivermectin levels after enteral and subcutaneous administration for Strongyloides hyperinfection: a case report. Scand J Infect Dis 2010; 42:234-236.
51. Lichtenberger P, Rosa-Cunha I, Morris M, et al. Hyperinfection strongyloidiasis in a liver transplant recipient treated with parenteral ivermectin. Transpl Infect Dis 2009; 11:137-142.
52. Boussinesq M, Kamgno J, Pion SD, Mackenzie CD. Erythropoietin for treating postivermectin Loa-related serious adverse events? Trends Parasitol 2010; 26:4-5.